Tagged with M&A

France The biggest recent stories from French healthcare and the life sciences, including Sanofi’s deal to buy immunology biotech Blueprint; the largest from a European pharma this year. Elsewhere Servier is snapping up a experimental leukaemia treatment from China, while French tech firm OWKIN is touting a new “AI-powered research co-pilot”…

USA Regeneron has agreed to pay USD 256 million to acquire at-home DNA test maker 23andMe after the troubled firm declared bankruptcy. Through the buyout, Regeneron will acquire the data of 23andMe’s customers, obtaining the valuable genetic profiles of millions to potentially develop new and lucrative therapies. With ambiguous legal guidelines…

Global Regular contributor Brendan Shaw looks ahead to a potentially turbulent 2025 for the pharmaceutical industry, highlighting five key trends that industry stakeholders must carefully navigate over the coming 12 months.   As pharma companies gear up for another year – a year that marks a quarter of the way through…

China Beyond political, cultural, economic, and linguistic concerns, the sheer pace of Chinese pharma’s development makes it challenging for international observers to fully grasp the sector’s intricacies, challenges, and numerous opportunities. Thankfully, in order to untangle this complex web PharmaBoardroom spoke directly to the heads of PhIRDA – the association representing…

China Dr Yingjia Zhang and Simon Hua of leading China-based CRO Biometas delve into the company’s rapid expansion in the preclinical space, strategic growth plans, and its positioning in the global CRO market. Focused on both organic growth and potential acquisitions, Biometas is leveraging a strong client base in the US…

China Jens Ewert, Life Science and Health Care Industry Leader at Deloitte China, provides an in-depth analysis of the development of China’s healthcare landscape over the previous past four years. Ewert highlights key trends such as the growing role of local biopharma players, the impact of value-based pricing, and the changing…

Switzerland This interview explores the transformative journey of Tillotts Pharma under the leadership of CEO Thomas Tóth von Kiskér, who has guided the company from a small team in 1996 to a global player with a focus on in-house R&D, strategic M&A, and a commitment to patient-centric innovation. Priorities for continued…

USA As Donald Trump assembles his new government, speculations about the consequences of his second presidential term abound. For the life sciences industry, the US president-elect’s more business-friendly stances could entail the repeal of the much-debated Inflation Reduction Act (IRA) while the naming of vaccine sceptic Robert F. Kennedy Jr as…

Switzerland Switzerland, home to industry giants like Novartis and Roche, boasts a thriving pharma industry that generates some seven percent of the country’s GDP, as well as a flourishing biotech scene. However, all is not so well in Switzerland’s domestic healthcare landscape, where surging insurance premiums and drug costs mean that…

China Global pharma has been stepping up M&A activity in Asia while also looking to access Asian markets through local partners and tap into the region’s huge growth potential. As a result, the role of Business Development (BD) at international pharma companies has evolved. In a recent PharmaBoardroom interview, Servier’s Asia…

Saudi Arabia Karim Smaira and Kamel Ghammachi, founders of Genpharm, underscores the strategic significance of the recent majority acquisition by Abdul Latif Jameel Health, part of Abdul Latif Jameel, driven by a shared vision and the imperative for accelerated growth. They discuss their expansion into diverse therapeutic areas, emphasizing the importance of…

China In recent years, global pharma’s Business Development (BD) operations in Asia have evolved from primarily managing global agreements locally to engaging in more complex tasks like contract negotiation and due diligence. Servier’s Asia BD Head Cynthia Xin Wang explains how this shift reflects changing market dynamics and the growing importance…